View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 9, 2020updated 30 Mar 2021 6:28am

Humanigen signs Covid-19 therapy development deal with US

Humanigen has signed an agreement with the US Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop lenzilumab for Covid-19 treatment.

Humanigen has signed an agreement with the US Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop lenzilumab for Covid-19 treatment.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The Cooperative Research and Development Agreement (CRADA), signed in partnership with the Biomedical Advanced Research and Development Authority (BARDA) aims to aid the government’s Operation Warp Speed programme.

Humanigen’s lenzilumab is a Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

It can potentially prevent and treat an immune hyper-response called a cytokine storm, which is seen as a leading cause of death in Covid-19 patients.

The CRADA will aid Humanigen in developing the treatment through access to a full-scale, integrated team of manufacturing and regulatory subject matter experts and statistical support.

This will progress its efforts to obtain emergency use authorisation (EUA) and subsequently a biologics license application (BLA) for lenzilumab as a potential treatment for the disease.

Under the agreement, Humanigen and federal experts will work on the US Food and Drug Administration (FDA) matters, meetings and regulatory filings.

The agreement will support the ongoing lenzilumab Phase III trials to efficiently generate EUA and BLA submissions.

Humanigen CEO Cameron Durrant said: “We are honoured to be part of Operation Warp Speed, receive this CRADA, and collaborate with JPEO-CBRND to advance lenzilumab as a potential response treatment and seek a potential EUA.

“We have been working tirelessly to advance lenzilumab for Covid-19 and are excited to have the integrated expert team at OWS prioritise lenzilumab research and development during this critical time.”

Lenzilumab is also part of the US National Institutes of Health’s ACTIV-5/BET trial being carried out in up to 40 sites across the US.

Last week, Humanigen entered into a licensing agreement with Telcon RF Pharmaceutical and KPM Tech for development and commercialisation rights of lenzilumab for South Korea and the Philippines.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology